UK guidelines for use of erythromycin chemoprophylaxis in persons exposed to pertussis

Journal of Public Health Medicine

Volumn 24, Issue 3, 2002, Pages 200-206

  Dodhia, Hiten ^a   Crowcroft, Natasha S ^b   Bramley, J Claire ^c   Miller, Elizabeth ^b  

^a Lambeth Southwark and Lewisham Health Authority   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c Scottish Centre for Infection and Environmental Health   (United Kingdom)

Author keywords

Erythromycin chemoprophylaxis; Guidelines; Pertussis vaccine; Whooping cough

Indexed keywords

ERYTHROMYCIN; AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; PERTUSSIS VACCINE;

ANTIBIOTIC PROPHYLAXIS; CHILD; FEMALE; HEALTH SERVICES RESEARCH; HUMAN; MALE; PERTUSSIS; PRACTICE GUIDELINE; PRESCHOOL CHILD; REVIEW; RISK FACTOR; STANDARD; UNITED KINGDOM; ABDOMINAL PAIN; ANTIBIOTIC THERAPY; BORDETELLA PERTUSSIS; CLINICAL ARTICLE; DOSE RESPONSE; DRUG USE; GASTROINTESTINAL SYMPTOM; HYPERTROPHIC PYLORUS STENOSIS; INFANT; INFECTION PREVENTION; NAUSEA; NEWBORN; PRIORITY JOURNAL; VACCINATION; VOMITING;

ANTIBIOTIC PROPHYLAXIS; CHILD; CHILD, PRESCHOOL; ERYTHROMYCIN; FEMALE; GREAT BRITAIN; HEALTH SERVICES RESEARCH; HUMANS; MALE; PRACTICE GUIDELINES; RISK FACTORS; WHOOPING COUGH;

EID: 0036740810     PISSN: 09574832     EISSN: None     Source Type: Journal    
DOI: 10.1093/pubmed/24.3.200     Document Type: Review

References (24)

1. Hodder SL, Mortimer EA. Epidemiology of pertussis and reactions to pertussis vaccine. Epidemiol Rev 1992; 14: 243-267.
2. Muller AS, Leeuwenburg J, Pratt DS. Pertussis: epidemiology and control. Bull WHO 1986; 64: 321-331.
3. Pollock TM, Miller E, Lobb J. Severity of whooping cough in England before and after the decline of pertussis immunisation. Arch Dis Child 1984; 59: 162-165.
4. Ramsay ME, Farrington CP, Miller E. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect 1993; 111: 41-48.
5. Statutory notifications for England and Wales, Northern Ireland and Scotland from PHLS CDSC Colindale and Northern Ireland and SCIEH.
6. Ranganathan S, Tasker R, Booy R, et al. Pertussis is increasing in unimmunised infants: is a change in policy needed? Arch Dis Child 1999; 80: 297-299.
7. de Serres G, Boulianne N, Douville FM, Duval B. Pertussis in Quebec: ongoing epidemic since the late 1980s. Can Commun Dis Rep 1995; 21: 45-48.
8. Anonymous. Resurgence of pertussis - United States. MMWR 1993; 42: 952-953, 959-960.
9. Howell F, Jennings S. The epidemiology of pertussis in the Republic of Ireland. Commun Dis Rep Rev 1992; 2: R31-R33.
10. MacIntyre R, Hogg G. Surveillance for Bordetella pertussis infection in Victoria. Aust J Publ Hlth 1994; 18: 21-24.
11. de Melker HE, Conyn-van Spaendonck MAE, Rumke HC, et al. Pertussis in the Netherlands: an outbreak despite high levels of immunisation with whole-cell vaccine. Emerg Infect Dis 1997; 3: 175-178.
12. Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect 1998; 120: 143-149.
13. Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomised, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 1999; 104(4): e42.
14. Granstrom G, Sterner G, Nord CE, Granstrom M. Use of erythromycin to prevent pertussis in newborns of mothers with pertussis. J Infect Dis 1987; 155: 1210-1214.
15. Van Buynder PG, Owen D, Vurdien JE, et al. Bordetella pertussis surveillance in England and Wales: 1995-1997. Epidemiol Infect 1999; 123: 403-411.
16. Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developers' handbook, updated April 2002, www.sign.ac.uk/guidelines/fulltext/50/section6.html (26 February 2002, date accessed).
17. Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999; 354: 2101-2105.
18. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001; 139(3): 380-384.
19. Richardson M, Elliman D, Maguire H, Simpson J, Nicoll A. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 2001; 20: 380-391.
20. PHLS Meningococcal Infections Working Group and Public Health Medicine Environment Group. Control of meningococcal disease: guidance for consultants in communicable disease control. CDR Rev 1995; 5(13): R189-R195.
21. British National Formulary, No. 42. September 2001.
22. Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001; 20: 1149-1154.
23. Salisbury D, Begg N, eds. Immunisation against infectious disease. Department of Health, Welsh Office, Scottish Office Department of Health, DHSS (Northern Ireland). London: HMSO, 1996.
24. From the Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceutical Officer. Current vaccine and immunisation issues. London: Department of Health, October 2001.